Sanara Medtech Inc
NASDAQ:SMTI
P/FCFE
Price to FCFE
Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
Market Cap | P/FCFE | ||||
---|---|---|---|---|---|
US |
Sanara Medtech Inc
NASDAQ:SMTI
|
263.9m USD | 44.8 | ||
CH |
Alcon AG
SIX:ALC
|
39.4B CHF | 135.2 | ||
JP |
Hoya Corp
TSE:7741
|
6.6T JPY | 41.6 | ||
DK |
Coloplast A/S
CSE:COLO B
|
191.9B DKK | 69.9 | ||
US |
Align Technology Inc
NASDAQ:ALGN
|
20.3B USD | 33.4 | ||
US |
Cooper Companies Inc
NYSE:COO
|
19.3B USD | 82.8 | ||
CN |
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
58.3B CNY | 51.5 | ||
UK |
ConvaTec Group PLC
LSE:CTEC
|
5.2B GBP | 39 | ||
KR |
H
|
HLB Inc
KOSDAQ:028300
|
8.7T KRW | -71.9 | |
US |
DENTSPLY SIRONA Inc
NASDAQ:XRAY
|
5.8B USD | 26.3 | ||
US |
Lantheus Holdings Inc
NASDAQ:LNTH
|
5.5B USD | 27 |
P/FCFE Forward Multiples
Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.